⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2022JAMAOpen Access

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant

Emma Birnie Jason J. Biemond Brent Appelman Godelieve J. de Bree Marcel Jonges Matthijs R. A. Welkers W. Joost Wiersinga

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study investigates whether resistance-associated mutations develop after treatment with sotrovimab in high-risk patients infected with the SARS-CoV-2 Omicron variant.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Birnie et al. (2022) studied this question.

synapsesocial.com/papers/6a8021571024bacc96928d2c https://doi.org/10.1001/jama.2022.13854

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)Prognostic Study · 2020 · 4,608 citations
2Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19RCT · 2022 · 279 citations
3SARS-CoV-2 Variants in Patients with ImmunosuppressionOriginal Research · 2021 · 437 citations
4Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab UseOriginal Research · 2022 · 164 citations
5Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and ErythropoiesisJAMA · Sat,

More from JAMA

Increased Hemoglobin With Sodium-Glucose Transporter 2 Inhibitors—A Consistent Extra Benefit?Sat,
Global Heart Failure Burden Increased Between 1990 and 2023Fri,
ACC Releases Guidance for Managing Resistant HypertensionFri,
Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance TherapyThu,
A Technology Journalist Looks at AI and HealthThu,